FTC May Go After Pharma Bundling, Rebates, Patent Processes With Reactivation of Section 5
Executive Summary
Agency restores long dormant enforcement of section of FTC Act prohibiting businesses from using ‘unfair methods of competition,’ expanding types of corporate behavior subject to enforcement action.
You may also be interested in...
FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.
FTC Set To Take Enforcement Action Against Drugmakers Over Orange Book Patent Listings
Merger reviews could take into account sponsor's Orange Book behavior. FTC's statement does not detail what would make a patent listing 'improper' but the precedents from court cases against various sponsors should offer industry some guideposts.
FTC Targets Amgen Bundling And Rebates In Suit To Block Horizon Acquisition
Complaint marks first time agency has raised novel theories of competitive harm in pharma merger and is rare instance in which it has filed a complaint without a consent decree. Last time FTC has gone to court to block a pharma merger was in 2008.